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Teduglutide, a glucagon-like peptide-2 analogue, increases 
intestinal adaptation and promotes intestinal absorption in 
patients with short bowel syndrome, based on several trials. A 
subset of patients was able to gain independence from paren-
teral support (parenteral nutrition and/or intravenous fluids). 
In most patients, oral or enteral autonomy was achieved after 
≥1 year of teduglutide, suggesting accrued response to treat-
ment. The wide range of disease and clinical characteristics is 
described for clinicians managing patients with short bowel 
syndrome considering treatment with teduglutide.
Introduction
Patients with intestinal failure associated with short bowel syn-
drome (SBS-IF) do not absorb sufficient fluid and nutrients 
through oral or enteral intake alone because of substantial intes-
tinal resection or functional impairment. Many of these patients 
require complete or partial parenteral support (PS; parenteral 
nutrition [PN] and/or intravenous [IV] fluids).1 Although PS is 
lifesaving therapy, chronic PS dependence increases the risk of 
serious medical complications, including central venous cathe-
ter–related bloodstream infections and liver damage.2
Teduglutide is a recombinant analogue of the endogenous 
intestinotrophic hormone glucagon-like peptide-2 (GLP-2) and 
is the first targeted therapy to enhance absorptive capacity in 
patients with SBS-IF.3–5 In phase III, placebo-controlled stud-
ies and their long-term extensions, patients receiving teduglu-
tide achieved and maintained clinical responses to treatment, 
as evidenced by reductions in weekly PS volume, additional 
days off from PS infusion, and total independence from PS for 
some patients.3,5–8 The safety profile of teduglutide during the 
placebo-controlled studies was consistent with its mechanism 
of action and with SBS-IF and its underlying causes.3,5,9 The 
most common adverse events (AEs) were gastrointestinal, 
including abdominal pain, nausea, and stoma enlargement; 
serious AEs (SAEs) included catheter-related complications, 
small intestinal obstruction, fever, and cholecystitis. Other AEs 
of special interest identified in the placebo-controlled studies 
and their long-term extensions were malignancy; colorectal 
polyps; gastrointestinal (GI) obstruction; gallbladder, biliary, 
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Abstract
Background: In phase III clinical studies, treatment with teduglutide was associated with clinically meaningful reductions (≥20% 
from baseline) in parenteral support (PS; parenteral nutrition and/or intravenous fluids) requirements in adult patients with intestinal 
failure associated with short bowel syndrome (SBS-IF). This analysis reports clinical characteristics of patients who achieved complete 
independence from PS during teduglutide treatment. Materials and Methods: Post hoc analysis of adult patients who achieved complete 
PS independence during treatment with teduglutide 0.05 mg/kg/d. Data were pooled from 5 teduglutide clinical trials (2 phase III 
placebo-controlled trials [NCT00081458 and NCT00798967] and their respective extension studies [NCT00172185, NCT00930644, 
NCT01560403]). Descriptive statistics were used; no between-group comparisons were performed because of the small sample size 
and lack of comparator. Results: Of 134 patients, 16 gained oral or enteral autonomy after a median of 5 years of PS dependence and 
89 weeks of teduglutide treatment. Demographic and baseline disease characteristics varied among patients (median age, 55 years; 
50% men; median baseline PS volume, 5.1 L/wk; median residual small intestine length, 52.5 cm). Most patients who achieved PS 
independence had colon-in-continuity; however, there was no significant difference in the frequency of PS independence among patients 
who maintained colon-in-continuity vs those who did not. Conclusion: Findings from this post hoc analysis suggest that oral or enteral 
autonomy is possible for some patients with SBS-IF who are treated with teduglutide, regardless of baseline characteristics and despite 
long-term PS dependence. (JPEN J Parenter Enteral Nutr. XXXX;xx:xx-xx)
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and pancreatic disease; fluid overload; and increased absorp-
tion of concomitant oral medications.10
To gather more information about the efficacy and safety of 
teduglutide treatment and the conditional nature of PS depen-
dence, this analysis was undertaken to report the characteristics 
of adult patients treated for up to 42 months with teduglutide at 
a subcutaneous dose of 0.05 mg/kg/d who have achieved oral or 
enteral autonomy in 2 phase III placebo-controlled studies and 
their respective extensions. Enteral autonomy was defined as 
complete independence from PS that occurred during treatment 
with teduglutide, subsequent to pretreatment standard-of-care 
optimization, including dietary and antidiarrheal therapy and 
stabilization of PS administration.3,5,7,8
Methods
Included Studies
Adult patients with SBS who required PS ≥3 times weekly for 
≥12 months were enrolled in 2 phase III, multicenter, random-
ized controlled trials (RCTs)3,5 or their respective extension 
studies.6–8 Study NCT00081458 (ClinicalTrials.gov identifier; 
EudraCT, 2004-000438-35) and STEPS (NCT00798967; 
EudraCT, 2008-006193-15) were 24-week, double-blind RCTs 
of subcutaneous teduglutide (0.05 or 0.10 mg/kg/d in 
NCT00081458 and 0.05 mg/kg/d in STEPS).3,5 Study 
NCT00172185 was a double-blind, 28-week extension of 
NCT00081458.7 In study NCT00172185, patients who 
received teduglutide in NCT00081458 continued on the same 
teduglutide dose in the extension study, and patients who 
received placebo were randomized 1:1 to treatment with sub-
cutaneous teduglutide 0.05 or 0.10 mg/kg/d. Total treatment 
time for patients who received teduglutide in NCT00081458 
and completed the NCT00172185 extension was 1 year. 
STEPS-2 (NCT00930644; EudraCT, 2009-011679-65) was a 
2-year, open-label extension of the phase III STEPS RCT.8 
Patients were eligible to enroll in STEPS-2 if they had com-
pleted either the placebo or teduglutide arm of STEPS. In addi-
tion, patients who completed the fluid optimization and 
stabilization phase in STEPS but were not randomized to treat-
ment because of full study enrollment could be enrolled 
directly into STEPS-2. All patients received subcutaneous 
teduglutide 0.05 mg/kg/d. STEPS-3 (NCT01560403) was a 
1-year open-label extension of STEPS-2; total treatment time 
for patients who received teduglutide in STEPS and completed 
STEPS-2 and STEPS-3 was 42 months.6 Full eligibility criteria 
for these studies have been published previously.3,5,7
All studies were conducted in compliance with International 
Conference on Harmonisation Good Clinical Practice guide-
lines and the World Medical Association Declaration of 
Helsinki and its amendments. Local institutional review boards 
or medical ethics committees approved all protocols, and all 
study patients provided informed consent. Study authors had 
access to all study data, and all approved the final manuscript.
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Protocol for Parenteral Support 
Optimization and Adjustments
Before randomization in the placebo-controlled studies, fluid 
balance was optimized and stabilized for up to 16 weeks using 
a standardized protocol to ensure adequate hydration status and 
urine output (target: 1–2 L/d) across all patients and clinical 
sites.3,5 Baseline values for PS requirements were determined 
following completion of the optimization/stabilization phases 
for all patients and at the start of teduglutide treatment (at the 
time of randomization for patients who received teduglutide in 
study NCT00081458 or STEPS and at the time of enrollment 
into the extension studies for all other patients). In all studies, 
patients were managed according to an algorithm that permit-
ted PS reductions of 10%–30% of baseline volume if clinical 
status was stable and 48-hour urine output had increased by 
≥10% over baseline.3,5,7,8 PS reductions were made at 2- to 
4-week intervals in the placebo-controlled trials; the weaning 
algorithm was less aggressive in the extension studies, where 
PS reductions were possible at 2- to 12-week intervals.
Protocol for Antibody Assessment
Details regarding the detection methods of potential 
antiteduglutide antibody formation were previously 
published.3,7 Briefly, formation of antibodies to teduglutide 
was assessed using the Meso Scale Discovery method, and 
the neutralizing antibody assay was a functional adenosine 
3′,5′-cyclic monophosphate accumulation assay.
End Points and Statistical Analysis
This post hoc analysis of pooled data evaluated the percentage 
of patients who achieved independence from PS during treat-
ment with teduglutide 0.05 mg/kg/d, the dose approved by the 
U.S. Food and Drug Administration and the European 
Medicines Agency.10,11 Treatment-emergent AEs (TEAEs) and 
treatment-emergent SAEs (TESAEs) for patients who achieved 
independence from PS were coded using the Medical 
Dictionary for Regulatory Activities. A χ2 test and Fisher exact 
test were used to analyze the frequency of PS independence in 
patients who maintained colon-in-continuity and those who 
did not. All other end-point analyses were performed using 
descriptive statistics. No additional between-group compari-
sons or correlations were performed in this patient population 
because of the nature of the extension studies and small patient 
numbers.
Results
In the combined phase III studies, 16 (12%) of 134 patients 
treated with teduglutide 0.05 mg/kg/d achieved complete inde-
pendence from any PS during the study treatment period. 
These patients gained oral or enteral autonomy after a median 
of 5 years (range, 2–18 years) of PS dependence. Table 1 
reports the baseline demographics, baseline disease character-
istics, exposure to teduglutide at the time of PS reductions, and 
exposure to teduglutide at the time of PS independence. The 
baseline demographics and disease characteristics of the 
16 patients (50% men) varied: age was 34–69 years (median, 
55 years), baseline PS volume was 3.5–13.4 L/wk (median, 5.1 
L/wk), and baseline PS infusion days per week was 3–6 days 
(median, 4 days). Remaining small intestine length ranged 
from 26–250 cm (median, 52.5 cm). Causes of resection were 
mesenteric vascular events (n = 8), injury (n = 2), Crohn’s dis-
ease (n = 2), complications of surgery (n = 2), ulcerative colitis 
(n = 1), and radiation enteritis (n = 1). Most patients who 
achieved PS independence had at least partial colon-in-conti-
nuity (12/16; 75%); however, 4 patients (25%) had no colon-
in-continuity. Among the 134 patients, there was no significant 
difference in the frequency of PS independence among patients 
who maintained colon-in-continuity vs those who did not 
(P = 0.3 and P = 0.4, χ2 and Fisher exact test, respectively). Of 
the 4 patients with no colon-in-continuity who achieved PS 
independence, their estimated remnant small bowel length was 
approximately 250 cm (n = 2) or was unknown (n = 2), and 
their baseline PS volume was 3.5, 13.0, 6.3, and 8.9 L/wk, 
respectively.
Most patients (12/16, 75%) had received ≥1 year of 
teduglutide therapy before PS could be eliminated (Figure 1). 
Oral or enteral autonomy was achieved after 12–130 weeks 
(median, 89 weeks) of teduglutide treatment; PS decreases 
were observed between 1 and 827 days after initiation of 
teduglutide. The change in body weight, body mass index 
(BMI), plasma citrulline (a biomarker of intestinal mucosa 
mass), serum albumin, and serum creatinine between baseline 
and end of teduglutide treatment is reported in Table 2. Median 
percentage change at end of teduglutide treatment was 0.3% 
(range, −16% to 12%) in body weight/BMI, 28.3% (range, 
−34% to 198%) in plasma citrulline, 2.3% (range, −8% to 
27%) in serum albumin, and −6.1% (range, −25% to 50%) in 
serum creatinine.
All patients who achieved independence from PS experi-
enced >1 TEAE, the most common of which were abdominal 
pain (n = 9), nausea (n = 7), diarrhea (n = 5), nasopharyngitis 
(n = 5), pain in extremity (n = 4), stoma complications (swell-
ing, protrusion, or increased intermittent flow, n = 3), and 
injection site complication (erythema, hematoma, or infection, 
n = 4). Central line infections occurred in 2 patients; none of 
the 16 patients were hospitalized. Nineteen TESAEs occurred 
in 13 patients. The only TESAEs reported in >1 patient were 
catheter-related infections (n = 4). TESAEs occurring in 
1 patient each were acute cholecystitis, hemorrhoids, catheter 
sepsis, abdominal pain, superior vena cava stenosis, urinary 
tract infection, deep vein thrombosis, lactic acidosis, implant 
site extravasation, delusional disorder (unspecified type), 
pneumonia, hydronephrosis, nephrolithiasis, catheter-related 
complication, and gastroenteritis. Teduglutide-specific anti-
bodies were detected in 3 of 16 (19%) patients; no neutralizing 
antibodies to teduglutide were detected.
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Discussion
Teduglutide therapy (0.05 mg/kg/d) was associated with com-
plete independence from PS for 16 of 134 (12%) treated patients 
with SBS-IF during their respective active treatment periods. All 
16 patients in this post hoc analysis of pooled clinical study data 
achieved PS independence only after treatment with teduglutide; 
no patient in the placebo groups within the subset of randomized 
controlled studies was weaned of PS.5,8 Seventy-five percent of 
patients received at least 1 year of teduglutide therapy before PS 
could be eliminated, including 1 patient who weaned off PS after 
2.5 years of treatment. In fact, the patient who achieved oral or 
enteral autonomy after 2.5 years (130 weeks) had the initial ben-
efit in PS reductions begin after 118 weeks of teduglutide treat-
ment. Considered in the context that PS volume reductions were 
associated with continued teduglutide treatment for up to 3.5 
years in long-term clinical studies,6–8 the PS independence data 
also suggest that teduglutide is associated with PS benefits 
accrued over time; thus, regular monitoring as part of individual-
ized patient management is recommended.
The adult patients with SBS who enrolled in the phase III 
teduglutide studies had a wide range of underlying disease 
characteristics, including varying remnant bowel anatomy. The 
prognostic factors previously associated with spontaneous 
adaptation, such as remnant bowel length or colon-in-continu-
ity, did not clearly predict teduglutide-induced enteral auton-
omy in this study.12,13 The remaining small intestine length 
ranged from 26–250 cm. Although most patients who achieved 
Figure 1. Duration of teduglutide treatment at time of PS 
independence. Bars represent the length of time in weeks that 
a patient was on teduglutide when independence from PS was 
achieved. Shading on the bars represents the clinical study 
treatment period that the patient was enrolled and receiving 
teduglutide when PS independence was obtained. PS, parenteral 
support (parenteral nutrition and/or intravenous fluids).








Duration of PS 
Dependency at 
Start of TED, y
PS Requirement 
at Start of TED, 
L/wk
PS Infusion 
Requirement at Start of 
TED, Days per Week
Weeks on 
TED at PS 
Weaning Cause for Resection
61, M Yes 80 6 3.5 3.5 12 Mesenteric infarction
54, M Yes 28 16 5.4 3 16 Mesenteric venous 
thrombosis
46, F No 250 1 3.5 3.5 28 Crohn’s disease
50, M No 250 1 13.0 6 32 Ulcerative colitis
66, M Yes 48 2 10.6 4.7 53 Ischemic bowel
39, M Yes 50 13 6.8 3 75 Injury
60, F No Unknown 2 6.3 3.5 79 Complications of 
surgery
66, F Yes 80 7 4.4 3 89 Radiation enteritis
46, M No Unknown 6 8.9 4 89 Crohn’s disease
34, M Yes 50 2 4.6 3 90 Mesenteric artery 
thrombosis
69, F Yes 120 5 3.5 3 101 Mesenteric arterial 
infarction
61, F Yes 76 1 4.1 4.5 101 Strangulated SI
63, M Yes 26 16 13.4 4.5 115 Mesenteric thrombosis
43, F Yes 40 2 4.5 5 126 Small bowel infarction
56, F Yes 50 2 9.4 6 127 Complications of 
surgery
41, F Yes 55 3 4.7 5.5 130 Injury
F, female; M, male; PS, parenteral support (parenteral nutrition and/or intravenous fluids); SI, small intestine; TED, teduglutide.
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independence from PS had colon-in-continuity (12/16), χ2 and 
Fisher exact tests did not show a significant association 
between the presence or absence of colon-in-continuity and PS 
weaning, perhaps because of small patient numbers.
The possible role of citrulline as a biomarker remains 
unclear. In this report, the percentage change from baseline in 
citrulline levels ranged from −34% to 198% in the 16 patients 
who achieved oral or enteral autonomy while on teduglutide 
therapy. Furthermore, no clear pattern emerges when the dura-
tion of teduglutide exposure before PS independence and the 
change in citrulline is examined in the individual patient.
Median body weight and BMI remained stable in patients 
who were weaned from PS during the study period (+0.3% 
change from baseline). Although 6 patients experienced weight 
loss >5% (range in weight variation for all patients, −16.3% to 
11.6%), all patients in the study maintained a BMI >18.5 kg/
m2. Based on median body weight, BMI, serum albumin, and 
creatinine levels, PS independence was achieved with a non-
compromised hydration and nutrition status. Median serum 
albumin was steady during the study (+2.3% change from 
baseline). At end of treatment, only 1 patient had serum albu-
min below 35 g/L, the lower limit of normal; this individual 
began teduglutide treatment with low serum albumin. Median 
serum creatinine was normal in 14 of 16 patients who achieved 
oral or enteral autonomy while on teduglutide therapy (2 
patients had high but not clinically significant levels). 
Collectively, median serum creatinine decreased during tedu-
glutide treatment (−6.1% change from baseline).
The safety profile of teduglutide in patients who achieved 
independence from PS was generally consistent with the safety 
profile of the phase III clinical study populations as a whole.3,5–8 
The most frequent TEAEs in this cohort of patients were GI 
symptoms, which are common among patients with SBS-IF.9 
The only TESAEs that occurred in >1 patient were catheter-
related infections, highlighting the need for careful catheter 
management in patients who are dependent on chronic PS. 
Patients in these studies achieved oral or enteral autonomy 
despite a relatively high incidence of TEAEs and TESAEs, 
suggesting that AEs can be managed to achieve optimal results 
with teduglutide.
This cohort of patients who obtained oral or enteral auton-
omy while receiving teduglutide all continued teduglutide 
treatment past the point of PS weaning until the end of the 
clinical study period. This pooled clinical trial post hoc analy-
sis was unable to add to the limited available data regarding 
outcomes of patients who discontinue teduglutide. However, 
3 patients in this cohort who participated in the NCT00081458 
and NCT00172185 studies were included in the Compher 
et al14 post hoc analysis that reported that all remained inde-
pendent of PS 12 months after withdrawal of 0.05 mg/kg/d 
teduglutide.7 Two of these patients had colon-in-continuity, 
and one had an end-jejunostomy. However, other evidence 
from the same analysis suggests that teduglutide discontinua-
tion may be associated with a rebound in PS requirements. 
Twelve of 25 patients who responded to teduglutide with a 
≥20% reduction in PS volume required increases in PS after 
Table 2. Nutrition and Clinical Characteristics of Patients at Baseline and Time of PS Independence.






































61, M 76.9 78.3 1.8 26.3 26.8 1.8 20.9 48.9 134.0 39 37 −5.1 151 140 −7.3
54, M 67.2 66.4 −1.3 21.9 21.7 −1.2 27.9 29.1 4.3 45 43 −4.4 106 80 −24.5
46, F 76.6 67.1 −12.4 29.6 25.9 −12.4 20.0 31.1 55.5 41 44 7.3 102 97 −4.9
50, M 74.8 79.3 6.0 26.5 28.1 6.0 17.0 16.7 −1.8 41 45 9.8 106 159 50.0
66, M 68.2 64.5 −5.4 25.4 24.0 −5.4 NA 25.0 NA 33 31 −6.1 71 106 49.3
39, M 63.8 67.0 5.0 22.6 23.7 5.0 12.0 15.4 28.3 47 47 0 74 83 12.2
60, F 64.3 61.2 −4.8 24.2 23.0 −5.0 28.0 25.8 −7.9 42 43 2.4 97 80 −17.5
66, F 48.8 46.0 −5.7 22.0 20.7 −5.7 18.0 43.1 139.4 42 49 16.7 72 78 8.3
46, M 84.6 93.0 9.9 27.9 30.7 9.9 34.0 57.8 70 48 44 −8.3 118 100 −15.3
34, M 67.5 75.3 11.6 24.5 27.3 11.6 20.0 14.2 −29 45 44 −2.2 66 65 −1.5
69, F 79.2 82.0 3.5 29.8 30.9 3.5 21.0 18.4 −12.4 37 47 27.0 53 65 22.6
61, F 51.0 42.7 −16.3 22.0 18.4 −16.4 20.0 40.4 102 38 35 −7.9 88 80 −9.1
63, M 59.0 58.1 −1.5 19.9 19.6 −1.5 11.0 24.1 119.1 40 41 2.5 105 96 −8.6
43, F 87.9 97.7 11.1 30.4 33.8 11.2 13.0 16.6 27.7 32 39 21.9 88 88 0
56, F 62.0 54.0 −12.9 24.5 21.4 −12.9 14.0 41.7 197.9 45 46 2.2 77 70 −9.1
41, F 55.2 56.9 3.1 20 20.6 3.0 28.0 18.4 −34.3 40 42 5 71 62 −12.7
BL, baseline; BMI, body mass index; EOT, end of treatment; F, female; M, male; NA, not available; PS, parenteral support (parenteral nutrition and/or 
intravenous fluids).
aReference range, 32−50 g/L.
bReference range, 40−119 µmol/L.
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stopping teduglutide.14 Compared with drug responders who 
maintained or decreased PS volume following teduglutide dis-
continuation, these 12 patients had shorter remnant small 
bowel (58 vs 35 cm, respectively) and were less likely to have 
colon-in-continuity (92% vs 57%), but neither observation 
reached statistical significance. In the current phase III exten-
sion study group as a whole, patients who received teduglutide 
0.05 mg/kg/d required a mean increase in PS of 1.5 L/wk 
between end of treatment and the 4-week follow-up visit.7 
These findings highlight the importance of individualized 
patient management with teduglutide and continued monitor-
ing after PS weaning. Patients who obtain oral or enteral auton-
omy still have their underlying condition of SBS and will 
likely continue to require specialized diets, vitamin and other 
micronutrient supplementation, concomitant antidiarrheal and 
other medications, and fluid optimization after weaning.15
This study was limited by the small patient sample size, 
which precluded performance of regression analyses for predic-
tive factors associated with PS independence. In addition, the 
studies pooled for this analysis included minor protocol 
differences that may have influenced rates of PS weaning. 
For example, the weaning algorithm in NCT00081458/
NCT00172185 permitted a 10% maximum reduction from 
baseline in PS volume during a PS adjustment vs a 30% maxi-
mum reduction in the STEPS study and its extension.3,5,7,8 The 
intervals between study visits were also shorter in the RCTs 
compared with the extension studies (2–4 vs 2–12 weeks, 
respectively). Furthermore, the influence of spontaneous intes-
tinal adaptation on PS weaning during the extension studies is 
currently unclear. Although most spontaneous intestinal adapta-
tion is thought to occur during the first 2 years following small 
bowel resection, recent studies indicate that adaptation can 
advance over longer time periods.12,16 Finally, the patients 
described here were managed under strict clinical trial proto-
cols and may not fully reflect the experiences of patients treated 
in general clinical practice. The ongoing teduglutide global reg-
istration study (ClinicalTrials.gov identifier: NCT01990040) 
will provide critical data regarding the efficacy and safety of 
teduglutide treatment under real-world conditions.
Together, these data indicate that oral or enteral autonomy is 
possible for some patients with SBS-IF who are treated with 
teduglutide, regardless of baseline characteristics and despite 
long-term dependence on PS. Studies involving larger patient 
populations are required to establish factors that may predict PS 
independence associated with teduglutide treatment. Oral or 
enteral autonomy in patients with SBS may be conditional, par-
ticularly during periods of metabolic stress and if teduglutide 
treatment is discontinued. Careful monitoring and individualized 
patient management can allow patients to obtain optimal results.
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